Pharmacokinetics

Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

by
Approval of New Class 1 Drug ADC by Lepu Biopharma for Clinical Trials

Recently, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that Lepu Biopharma’s Class 1 new drug MRG007 has been approved for clinical trials,aiming to develop treatments for locally advanced or metastatic solid tumors. Public information indicates that this is aCDH17-targeted antibody-drug conjugate (ADC),formed by conjugating a novel humanized … Read more

Introduction to ADC: A Brief Overview of Clinical Pharmacology

by
Introduction to ADC: A Brief Overview of Clinical Pharmacology

Introduction Antibody-drug conjugates (ADC) are comprised of monoclonal antibodies that target specific antigens linked to small molecule cytotoxic drugs via a linker, combining the powerful killing effects of traditional small molecule chemotherapy with the tumor-targeting properties of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin (trade name: Mylotarg)) was approved for the treatment of CD33-positive acute … Read more

Fundamentals of Clinical Pharmacology of ADCs

by

Antibody-drug conjugates (ADC) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs. Since the first ADC (Gemtuzumab-ozogamicin, trade name: Mylotarg) was approved for the treatment of CD33-positive acute myeloid … Read more